**Partial rescheduling of state-regulated medical marijuana and FDA-approved products to Schedule III took effect in late April 2026 following a December 2025 executive order directing expedited action.** An administrative hearing on broader rescheduling from Schedule I to Schedule III opened June 29, 2026, with a target conclusion by mid-July. The process stems from the 2024 proposed rule, public comments, and subsequent procedural resets that withdrew earlier hearing notices. Traders monitor the DEA’s post-hearing timeline for a final rule, any administrative law judge recommendations, and potential challenges or delays that could extend full implementation beyond 2026. Historical precedent shows administrative rescheduling can face extended reviews, while the current expedited track reflects explicit administration priorities on research access and state program alignment.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於$796,389 交易量
2026-03-31
9月30日
14%
12月31日
25%
$796,389 交易量
9月30日
$0 交易量
14%
12月31日
$186,818 交易量
25%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Partial rescheduling of state-regulated medical marijuana and FDA-approved products to Schedule III took effect in late April 2026 following a December 2025 executive order directing expedited action.** An administrative hearing on broader rescheduling from Schedule I to Schedule III opened June 29, 2026, with a target conclusion by mid-July. The process stems from the 2024 proposed rule, public comments, and subsequent procedural resets that withdrew earlier hearing notices. Traders monitor the DEA’s post-hearing timeline for a final rule, any administrative law judge recommendations, and potential challenges or delays that could extend full implementation beyond 2026. Historical precedent shows administrative rescheduling can face extended reviews, while the current expedited track reflects explicit administration priorities on research access and state program alignment.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
市場開放時間： Feb 7, 2026, 5:04 PM ET
交易量
$796,389結束日期
2026-03-31市場開放時間
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Partial rescheduling of state-regulated medical marijuana and FDA-approved products to Schedule III took effect in late April 2026 following a December 2025 executive order directing expedited action.** An administrative hearing on broader rescheduling from Schedule I to Schedule III opened June 29, 2026, with a target conclusion by mid-July. The process stems from the 2024 proposed rule, public comments, and subsequent procedural resets that withdrew earlier hearing notices. Traders monitor the DEA’s post-hearing timeline for a final rule, any administrative law judge recommendations, and potential challenges or delays that could extend full implementation beyond 2026. Historical precedent shows administrative rescheduling can face extended reviews, while the current expedited track reflects explicit administration priorities on research access and state program alignment.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
交易量
$796,389結束日期
2026-03-31市場開放時間
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...**Partial rescheduling of state-regulated medical marijuana and FDA-approved products to Schedule III took effect in late April 2026 following a December 2025 executive order directing expedited action.** An administrative hearing on broader rescheduling from Schedule I to Schedule III opened June 29, 2026, with a target conclusion by mid-July. The process stems from the 2024 proposed rule, public comments, and subsequent procedural resets that withdrew earlier hearing notices. Traders monitor the DEA’s post-hearing timeline for a final rule, any administrative law judge recommendations, and potential challenges or delays that could extend full implementation beyond 2026. Historical precedent shows administrative rescheduling can face extended reviews, while the current expedited track reflects explicit administration priorities on research access and state program alignment.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於
警惕外部連結哦。
警惕外部連結哦。
Frequently Asked Questions